Skip to contentB
Bioadaptives, Inc.
B
BDPTBioadaptives, Inc. Q2 2025 · 10-Q
Revenue$3.22K$3.22K+376.9% vs Q2 2024 Net Income-$157.91K-$157.91KN/M vs Q2 2024 EPS Diluted-$0.02-$0.02N/M vs Q2 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioadaptives, Inc. · CIK 1575142 · Engraved from SEC EDGAR
Operating Cash Flowderived-$110,982N/M Margins · derivedGross margin33.0%+96.6 pt vs Q2 2024
Operating margin-8674.1%+5100.4 pt vs Q2 2024
Net margin-4905.7%+22207.9 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end